a 29-residue copy of the first half of natural GHRH

Sermorelin is a synthetic peptide that copies the first 29 amino acids of growth hormone-releasing hormone, the hypothalamic hormone your body uses to ask the pituitary for a pulse of growth hormone. Natural GHRH is 44 residues long. Sermorelin is just the front half plus a chemical cap on the C-terminus, called a C-terminal amide. That trimmed copy turns out to do almost everything the full hormone does at the receptor, which is why researchers in the 1980s and 1990s built it as a defined, synthesizable replacement for native GHRH (Guillemin et al. 1982; Mayo 1992; Prakash and Goa 1999).

Sermorelin had a brief, formal medical life as Geref -- approved in the US in the mid-1990s for children with growth hormone deficiency, withdrawn from the market in 2008 for commercial reasons rather than safety failure. Today it lives on as a compounded peptide supplied through US 503A compounding pharmacies for off-label adult use. That history matters because it shapes everything about how the evidence base is structured: pediatric data are old and real, modern adult data are thin, and most "anti-aging" claims you will read online extrapolate from recombinant GH or tesamorelin studies rather than from sermorelin itself (Geref ISG 1996; Prakash and Goa 1999).

29 aa

N-terminal fragment of native GHRH(1-44)

1996

FDA-approved as Geref for pediatric GHD

~11 min

plasma half-life, cleared by DPP-IV

503A

current US supply route, compounded only

GHRH(1-29)-NH2 in plain terms

how a hormone discovered in a pancreatic tumor in 1982 became a defined, synthesizable peptide drug -- and why the first 29 residues were enough.

a hormone the hypothalamus uses to ask for a pulse

GHRH is a small peptide your hypothalamus releases into a private vein that runs straight to the front lobe of the pituitary gland. Cells there called somatotropes wear a matching receptor, GHRHR, and when GHRH binds, those cells release a stored burst of growth hormone into the bloodstream. The release is not a steady drip. It is a sequence of pulses, six to twelve a day, with the largest one happening shortly after you fall into deep sleep (Van Cauter and Plat 1996).

where the molecule came from

Roger Guillemin and Paul Brazeau isolated the first usable GHRH in 1982 -- not from a healthy hypothalamus, where the hormone is present in tiny amounts, but from a pancreatic tumor in a patient with acromegaly. The tumor was making GHRH ectopically and at huge concentrations, which gave the team enough material to sequence the peptide for the first time (Guillemin et al. 1982). The natural hormone turned out to be 44 amino acids long, with two slightly shorter variants in circulation.

why the first 29 residues were enough

Once GHRH was in hand, the next question was practical. Synthesizing 44 amino acids is hard and expensive. Could a shorter fragment work? Step-by-step trimming experiments showed that almost all of the receptor-activating power lived in the N-terminus. Cut the C-terminal 15 residues off and you still got a peptide that bound the GHRH receptor and triggered GH release. Cap the new C-terminus with an amide group and the resulting molecule was more stable than the raw cut sequence. That capped 29-residue fragment is sermorelin (Mayo 1992; Prakash and Goa 1999).

Y A D A I F T N S Y R K V L G Q L S A R K L L Q D I M S R-NH2 Q Q G E S N Q E R G A R A R L

native GHRH spans 44 residues. sermorelin keeps positions 1 through 29 and caps the new C-terminus with an amide (-NH2). the 15 trimmed residues do not carry the receptor-activating sequence.

advanced: why the C-terminal amide matters biochemistry

Free peptide C-termini are negatively charged carboxylates and a known target for carboxypeptidases. Capping the end with an amide group (-CONH2) removes the negative charge and stabilizes the alpha-helical conformation at the C-terminus -- which happens to be the region a class B GPCR like GHRHR uses as the anchor when its ligand docks. The amide is small but it does real work: it sharpens binding to the GHRH receptor extracellular domain and slows degradation by C-terminal proteases. This is why sermorelin is written GHRH(1-29)-NH2 rather than just GHRH(1-29).

key terms

definitions for the technical words that show up across this course. tap to expand.

sermorelin peptide

A 29-amino-acid synthetic peptide that copies the first 29 residues of natural growth hormone-releasing hormone, with a C-terminal amide. Written formally as GHRH(1-29)-NH2 and supplied as the acetate salt for injection. It is the molecule this course is about.

GHRH hormone

Growth hormone-releasing hormone. A 44-residue hypothalamic peptide released into the pituitary portal circulation that asks somatotrope cells in the anterior pituitary to release a pulse of growth hormone. Sometimes also written as GRF (growth-releasing factor), an older name for the same molecule (Guillemin et al. 1982).

GHRHR receptor

The GHRH receptor. A class B G-protein-coupled receptor, cloned by Kelly Mayo and colleagues in 1992 from pituitary tissue, expressed almost exclusively on the somatotropes of the anterior pituitary. This is the only receptor sermorelin needs to bind to do its job (Mayo 1992).

GH hormone

Growth hormone, also called somatotropin. A 191-amino-acid protein hormone made and stored in pituitary somatotropes and released into the blood in pulses. GH acts on liver, muscle, adipose, and bone, and most of its long-range anabolic effects are mediated by IGF-1 downstream.

somatotrope cell type

The GH-producing cell type of the anterior pituitary. Somatotropes are roughly 30 to 50 percent of anterior pituitary cells, store GH in dense secretory granules, and respond to GHRH, ghrelin, and beta-adrenergic input. They are inhibited by somatostatin and by IGF-1.

IGF-1 hormone

Insulin-like growth factor 1. A protein made mostly by the liver in response to GH, carried in blood by binding proteins (IGFBP-3 and ALS). IGF-1 mediates most of the growth-promoting and anabolic effects classically attributed to GH and is the workhorse downstream signal of the GH axis (Le Roith et al. 2001).

IGFBP-3 binding protein

IGF-binding protein 3. The principal carrier of circulating IGF-1. By keeping IGF-1 in a complex with IGFBP-3 and a third partner called the acid-labile subunit, the body extends IGF-1's effective half-life from minutes to hours. IGFBP-3 levels are commonly measured alongside IGF-1 in GH-axis testing.

somatostatin (SST, GHIH) hormone

The master inhibitor of GH release, sometimes still called growth-hormone-inhibiting hormone (GHIH). Made in the hypothalamic periventricular nucleus, it tells somatotropes to stop secreting GH. The natural rhythm of GH pulses is shaped by reciprocal waves of GHRH and somatostatin -- pulses happen when somatostatin is low (Tannenbaum and Ling 1984).

pulsatility physiology

The pattern of GH release as discrete bursts rather than a steady stream. In healthy adults GH pulses occur six to twelve times a day, with the largest pulse during slow-wave sleep. Preserving pulsatility is the central pharmacologic argument for sermorelin and other GHRH analogs versus recombinant GH (Van Cauter and Plat 1996; Van Cauter et al. 2000).

DPP-IV enzyme

Dipeptidyl peptidase-4. A serum protease that snips off pairs of amino acids from the N-terminus of certain peptides. It is the main reason sermorelin has a roughly 11 to 12 minute plasma half-life: it chews the Ala2-Asp3 bond at the front of the molecule. Tesamorelin and modified GRF analogs were engineered specifically to resist DPP-IV cleavage.

tesamorelin analog

A DPP-IV-resistant GHRH analog that adds a trans-3-hexenoic acid group to the N-terminus of GHRH(1-44). It is currently the only FDA-approved GHRH analog on the US market, approved for HIV-associated lipodystrophy and supported by Phase 3 data showing a roughly 15 percent visceral fat reduction at 26 weeks (Falutz et al. 2007; Stanley et al. 2012).

CJC-1295 analog

A modified GHRH(1-29) analog that resists DPP-IV cleavage. The "no-DAC" variant is essentially modified GRF(1-29) with a moderately extended half-life; the "DAC" variant (with a drug affinity complex linker that binds serum albumin) pushes the half-life out to roughly six to eight days but at the cost of losing the natural pulse pattern (Teichman et al. 2006).

interactive: from GHRH(1-44) down to sermorelin

a hands-on view of how natural GHRH was trimmed residue by residue until receptor-activating power concentrated in the first 29 positions. tap any residue to see what it contributes and what gets lost when you cut it.

GHRH(1-29)-NH2 minimal-fragment explorer

tap any residue of native GHRH(1-44) to see what it does and whether sermorelin keeps it (positions 1-29) or trims it (positions 30-44)

why 29 amino acids is enough

the GH/IGF-1 axis at a beginner level -- and why a short N-terminal fragment can do almost all the work of the full 44-residue hormone.

the chain of three signals

The growth hormone axis is a chain of three signals running from the brain to the rest of the body. The hypothalamus sends GHRH. The pituitary, in response, sends GH. The liver, in response to GH, sends IGF-1. IGF-1 is the molecule that does most of the long-distance work in muscle, bone, and tissue repair (Le Roith et al. 2001).

hypothalamus

arcuate nucleus releases GHRH into the pituitary portal vein

pituitary

somatotropes wear GHRHR; binding triggers a pulse of GH into blood

liver

GH receptor on hepatocytes drives IGF-1 production, carried by IGFBP-3

peripheral tissue

IGF-1 acts on muscle, bone, and connective tissue for growth and repair

why trimming the C-terminus works

Native GHRH binds GHRHR through a two-domain handshake. The C-terminal helix anchors first to the receptor's extracellular domain, holding the ligand in place. The N-terminal residues then swing into the receptor's transmembrane core, where they activate the signal. Trimming experiments showed that the anchoring part can be made shorter without losing receptor binding, as long as the active N-terminus stays intact (Mayo 1992; Prakash and Goa 1999). The first 29 residues carry both pieces -- the active head and enough of the anchor helix to dock the ligand stably. Capping with a C-terminal amide stabilizes the helix shape and protects against C-terminal proteases.

advanced: the Tyr-Ala-Asp N-terminus biochemistry

The first three residues of GHRH -- Tyr1-Ala2-Asp3 -- are the receptor-activating tip of the molecule. Removing or modifying them destroys agonist activity. They are also the target of DPP-IV, which cleaves between Ala2 and Asp3 and inactivates the peptide. That is the chemical tradeoff at the heart of GHRH-analog design: the part you cannot change without losing potency is the same part the body's main clearance enzyme attacks. Tesamorelin works around this by adding a trans-3-hexenoic acid cap to the N-terminus that physically blocks DPP-IV. CJC-1295 no-DAC substitutes the Ala2 residue for a D-amino-acid form that DPP-IV will not recognize.

the pulsatility argument

why a peptide with an 11-minute half-life is treated as a feature, not a bug -- and the central pharmacologic claim of this whole course.

GH does not run as a steady drip

Your body does not maintain a steady level of growth hormone. It pulses GH out of the pituitary six to twelve times a day, with the biggest pulse arriving shortly after you fall into slow-wave sleep. In between pulses, GH levels are very low -- often undetectable in standard assays. The signaling downstream cares about this pattern. Hepatic STAT5, the main GH-receptor-driven transcription factor in the liver, reads pulsed GH and continuous GH differently and turns on different gene programs in response (Van Cauter and Plat 1996; Van Cauter et al. 2000).

pulses versus a continuous plateau

pulsatile (sermorelin)

A SubQ dose at bedtime triggers a discrete GH pulse that peaks at roughly 15 to 60 minutes and returns to baseline within two to three hours. The pulse stacks on top of the body's existing sleep-onset pulse rather than replacing it. Somatostatin troughs still gate the timing, and IGF-1 negative feedback still works.

Downstream, IGF-1 rises gradually over days. Insulin sensitivity is preserved relatively well, because GH spends most of the day at baseline rather than at a counter-regulatory plateau.

continuous (rhGH or CJC-1295-DAC)

Daily recombinant GH injections or weekly DAC-linked analogs produce a steady, non-pulsing elevation of GH and IGF-1. The hepatic STAT5 program shifts. Insulin sensitivity drops measurably. Side effects long associated with rhGH in older adults -- edema, joint pain, carpal-tunnel symptoms, glucose intolerance -- track the continuous-exposure pattern (Liu et al. 2007).

This is the contrast sermorelin proponents point to: a longer half-life is not automatically better if it sacrifices the pattern.

why the short half-life is the point

A sermorelin dose comes and goes inside one GH pulse. The pituitary fires, somatostatin clamps the brake back on, and the system resets before the next pulse window. The body's negative-feedback loops -- IGF-1 on the hypothalamus, GH on the somatotropes, somatostatin on everything downstream -- stay intact (Berelowitz et al. 1981; Tannenbaum and Ling 1984). This is the structural reason sermorelin is much harder to push into supraphysiologic GH excess than recombinant GH is. The architecture is doing the regulation, not the prescriber.

advanced: receptor desensitization and tachyphylaxis pharmacology

Continuous receptor agonism downregulates surface receptor expression and uncouples G-protein responses through beta-arrestin recruitment and internalization. Intermittent stimulation allows resensitization between doses. Sermorelin's short half-life paradoxically protects responsiveness because the receptor spends most of its time unoccupied. Long-acting GHRH analogs that maintain continuous receptor engagement -- most notably CJC-1295-DAC -- risk somatotrope desensitization over weeks of dosing. This is one of the strongest pharmacologic arguments to teach sermorelin's pulse profile as a feature of the design, not a limitation to engineer away.

sermorelin vs recombinant GH

two ways to raise the GH/IGF-1 axis -- one bypasses the hypothalamus entirely, the other asks the body's own pituitary to do the work.

the regulatory backstory

Recombinant human growth hormone (rhGH, marketed as somatropin) is the standard-of-care treatment for diagnosed GH deficiency in both children and adults. It delivers exogenous GH directly into the bloodstream, bypassing the hypothalamus and pituitary entirely. That makes it powerful, predictable, and easy to titrate. It also disconnects GH levels from the body's normal feedback architecture, which is where the side-effect profile starts (Molitch et al. 2011).

where sermorelin sits in the picture

Sermorelin asks the body to make its own GH pulse instead. Same axis, different entry point. The trade is straightforward. With rhGH you can push IGF-1 to almost any level, and the body cannot stop you. With sermorelin, IGF-1 still rises -- but the body's feedback loops cap how high, and the rise stays inside a pulsatile pattern. Where rhGH plateaus, sermorelin pulses.

why this difference matters in practice

predictability vs preservation

rhGH wins on predictable IGF-1 elevation. Sermorelin wins on preserving the natural pulse pattern. Which matters more depends on the clinical context: pediatric GH deficiency needs predictable replacement; adult off-label use is debatable.

self-limiting response

Because sermorelin works through the intact pituitary, it is self-limiting. Even with off-label use, it is unlikely to drive the kind of supraphysiologic GH excess that rhGH overdose can produce. The structural protection is the feedback architecture itself.

evidence asymmetry

rhGH has decades of trials in adults including the Rudman 1990 body-composition study and the Liu 2007 meta-analysis. Sermorelin has solid pediatric data and very thin adult data. Most "anti-aging" claims you read about sermorelin are extrapolated from rhGH or tesamorelin (Rudman et al. 1990; Liu et al. 2007).

approved, withdrawn, compounded

why sermorelin exists today as a 503A bulk substance rather than as a branded FDA-approved product -- and why the 2008 withdrawal was not what most people assume.

1996: approved as Geref

Sermorelin acetate was approved by the FDA under the brand name Geref in the mid-1990s for diagnosis and treatment of growth hormone deficiency in children. The pivotal evidence came from a multicenter trial run by the Geref International Study Group: 110 prepubertal GH-deficient children, treated nightly with 30 mcg/kg of sermorelin subcutaneously, showed a significant first-year increase in growth velocity (Geref ISG 1996; Prakash and Goa 1999). This was the strongest direct sermorelin trial that has ever been run, and it remains the anchor for the entire pediatric GHD evidence base.

2008: withdrawn for commercial, not safety, reasons

In 2008, EMD Serono voluntarily withdrew Geref from the US market. The withdrawal was a business decision -- pediatric GHD treatment had become dominated by recombinant GH, which offered more predictable response and easier dose titration. The FDA later formally determined, and published in the Federal Register in 2013, that the withdrawal was not for reasons of safety or effectiveness (Federal Register 2013). That single distinction is the legal hinge for everything that came after.

U.S. Federal Register -- March 4, 2013

"Determination That GEREF (Sermorelin Acetate) Injection Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness."
FDA determination establishing that the 2008 Geref withdrawal was commercial, not safety- or efficacy-driven -- the regulatory basis for ongoing 503A compounding eligibility (Federal Register 2013).

today: a 503A bulk substance

Because the withdrawal was non-safety, sermorelin remained eligible for compounding under section 503A of the Federal Food, Drug, and Cosmetic Act -- the legal pathway for traditional pharmacies preparing medications for individual patients. The molecule appears on the FDA's 503A bulk drug substances landscape, where its category status has been reviewed across multiple PCAC meetings (FDA 503A bulks). The practical effect is that compounded sermorelin is widely supplied for adult off-label use, but no branded FDA-approved sermorelin product exists in the US.

why the community shifted away

Even after sermorelin remained legally compoundable, the off-label community partly moved on. CJC-1295 stacks with ipamorelin offered fewer injections and a marketing story around GHRH plus GHRP synergy (Bowers et al. 1990). Tesamorelin (Egrifta) became the only FDA-approved GHRH analog on the market, supported by real Phase 3 visceral-fat data in HIV-associated lipodystrophy (Falutz et al. 2007). Regulatory uncertainty around compounded peptides created supply churn that pushed users between analogs. The result is that sermorelin sits today as the original, evidence-anchored GHRH-axis compound -- still in use, less marketed, and with a longer history than any of its successors.

honest evidence ceiling

what is solid, what is suggestive, what is community-level, and what has not been studied in adequately powered modern trials.

solid

pediatric GHD growth response

Replicated, peer-reviewed historical findings backed by a multicenter pivotal trial.

nightly sermorelin at 30 mcg/kg significantly raised first-year growth velocity in GH-deficient children (Geref ISG 1996).
earlier GRF studies by Thorner and colleagues showed catch-up growth in GH-deficient children (Thorner et al. 1985).
FDA approval as Geref was supported by this direct human trial evidence, and the 2008 withdrawal was non-safety (Federal Register 2013).

moderate

GH-axis stimulation biology

The mechanism by which sermorelin raises GH and IGF-1 in humans is well established, even if outcome data are thin.

sermorelin reliably produces a discrete GH pulse 15 to 60 minutes after a SubQ dose in healthy adults.
repeated nightly dosing in older men raised pulsatile GH and IGF-1 toward younger-adult levels (Corpas et al. 1993).
the GHRH plus arginine test is a validated diagnostic tool for adult GHD and uses the same GHRH(1-29) pharmacology (Aimaretti et al. 2000; Ho 2007).

weak

adult somatopause and body composition

Biologically plausible but extrapolated from small uncontrolled sermorelin studies and from the larger rhGH literature in elderly populations.

a 16-week sermorelin-analog study in older men and women reported modest lean-mass gain and improved well-being, but was small and single-blinded (Khorram et al. 1997).
recombinant GH in healthy elderly produces small body-composition shifts plus measurable adverse events, with no functional gain (Rudman et al. 1990; Liu et al. 2007).
community recovery, sleep, and lean-mass claims rely heavily on extrapolation from rhGH or tesamorelin data, not from direct sermorelin trials (Sigalos and Pastuszak 2018).

missing

modern adult sermorelin RCTs

As of 2026, none of the following exist at scale.

no large modern randomized controlled trial of sermorelin in healthy adults for any cosmetic or anti-aging endpoint.
no head-to-head trial against tesamorelin or rhGH for adult endpoints.
no long-term safety dataset in adults using off-label sermorelin for months or years.
no validated adult dose set by an independent regulator -- community ranges of 200 to 500 mcg nightly are not formally established (Molitch et al. 2011).

The most common mistake when reading about sermorelin online is treating recombinant GH or tesamorelin trial results as if they were sermorelin data. The pediatric GHD evidence is real and historical. The adult somatopause and body-composition case rests almost entirely on extrapolation. This course separates the two carefully throughout, and the adult-use unit is explicit about what the small uncontrolled studies actually showed.

what you will learn

where this course goes from here.

The next nine units take this unit's overview and go much deeper, each one earning the "mastery" label by a different kind of depth. The chemistry unit dissects the 29-residue sequence and the DPP-IV cleavage site. The receptor signaling unit walks through the cAMP, PKA, and CREB cascade step by step. The pediatric GHD unit -- the marquee unit -- spends its entire runtime on the Geref evidence base and the historical FDA approval.

02

chemistry and structure

the 29-residue sequence amino acid by amino acid, the Tyr-Ala-Asp N-terminus, the C-terminal amide, and the DPP-IV cleavage site at Ala2-Asp3.
03

GHRH receptor signaling

how sermorelin engages GHRHR as a class B GPCR, drives the cAMP, PKA, and CREB cascade, and supports pulsatile GH release without overriding hypothalamic control.
04

the GH/IGF-1 axis

somatotrope physiology, hepatic IGF-1 production, somatostatin and IGF-1 negative feedback, and the pulsatile-versus-continuous distinction at the systems level.
05

pediatric GH deficiency

the marquee evidence unit. Thorner 1985, the Geref ISG 1996 pivotal trial, the FDA approval, and the 2008 commercial withdrawal in detail.
06

adult off-label use

somatopause biology, the small uncontrolled sermorelin studies, body-composition and recovery claims, and what modern trials have and have not shown.
07

sermorelin vs other GH-axis analogs

tesamorelin, CJC-1295 with and without DAC, ipamorelin, and MK-677 -- mechanism, half-life, approval status, and clinical evidence side by side.
08

safety and product quality

injection-site reactions, glucose handling, thyroid-axis effects, IGF-1 monitoring, and the red flags that come with compounded supply.
09

administration and regulatory status

subcutaneous dosing rationale, BAC water reconstitution, FDA 503A bulk substance context, WADA prohibited status, and community-protocol framing for educational use only.
10

final exam and certification

comprehensive exam covering all nine prior units. pass and earn a Sermorelin Specialist certificate.

By the end you should be able to read a paper, a Reddit post, or a vendor page about sermorelin and immediately tell which claims have direct trial evidence behind them, which are extrapolated from rhGH or tesamorelin, and which are pure marketing.

29

amino acid residues

10

units including final exam

~3 hours

estimated to complete the course

certificate

awarded on passing the final exam

Knowledge Check

confirm the GHRH(1-29) framing, the pulsatility argument, the Geref history, and the evidence-ceiling tiers before moving deeper.

Practice

reinforce the distinctions that matter most for the rest of the course.

what is sermorelin?